Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Basilea Pharmaceutica Ltd.. (2/11/14). "Press Release: Basilea 2013 Full-year Results – Strong Operational and Financial Performance. Cash and Short-term Investments of CHF 274 Million". Basel.

Organisations Organisation Basilea Pharmaceutica Ltd. (SIX: BSLN)
  Group Basilea (Group)
  Organisation 2 Astellas Pharma Inc. (TSE: 4503)
  Group Astellas (Group)
Products Product ceftobiprole
  Product 2 isavuconazole
Persons Person Scott, Ronald (Ron) (Basilea 201212–201804 CEO before COO before CFO RETIRED 2/18 proposed for Board)
  Person 2 Zink, Barbara (Basilea 201109 Head Corporate Development)
     


   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Basilea (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top